Does TNDM Stock Still Deserve a Place in Your Portfolio?
Tandem Diabetes Care (TNDM) is positioned for growth due to the increasing prevalence of diabetes and rising demand for automated insulin delivery systems, along with a new pay-as-you-go reimbursement model that may strengthen its financial position. However, the company faces potential headwinds from macroeconomic pressures, execution risks related to product platforms, and ongoing supply chain challenges. Despite these risks, the company's strong liquidity and long-term earnings growth rate suggest potential.
10 Best Get Rich Quick Stocks to Buy Right Now
This article identifies Tandem Diabetes Care, Inc. (NASDAQ: TNDM) as one of the best get-rich-quick stocks, citing its 86.03% upside potential and recent CE mark for expanded indications of its automated insulin delivery systems in Europe. Despite a "Hold" rating from Deutsche Bank due to execution risk, the company's commitment to innovation and more than half of analysts giving it a Buy rating highlight its strong market position. However, the author suggests that certain AI stocks may offer even greater returns with less downside risk.
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility With Abbott's FreeStyle Libre 3 Plus CGM Sensor
Tandem Diabetes Care has made its t:slim X2 insulin pump, featuring Control-IQ+ technology, compatible with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in several European countries, including the UK, Switzerland, Sweden, Finland, and Italy. This integration provides users with expanded CGM choices, allowing the FreeStyle Libre 3 Plus sensor to send glucose readings to the pump every minute for up to 15 days. The company plans to roll out this compatibility to additional countries later this year.
Tandem Diabetes faces earnings test as pay-as-you-go shift weighs
Tandem Diabetes Care Inc., an insulin-pump maker, is set to report its first-quarter earnings, with analysts anticipating a loss of 44 cents per share on $242.1 million in revenue. This projected decline is largely due to the company's transition to a pay-as-you-go pharmacy model, which is expected to create near-term revenue headwinds but improve long-term economics. Investors will be closely watching the execution speed of this transition, growth in new prescriptions for the Mobi system, and progress toward margin targets.
ETFs Investing in Tandem Diabetes Care, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Tandem Diabetes Care, Inc. The ETFs are sorted by their market value and include details such as issuer, management style, focus, expense ratio, assets under management (AUM), price, and 3-year NAV total return. The ETFs predominantly focus on small-cap, health care, and extended market sectors.
TNDM - Tandem Diabetes Care Inc Options
This article provides a detailed financial overview of Tandem Diabetes Care Inc. (TNDM), including its last closing price, market capitalization, key financial ratios, earnings per share, sales performance, and insider/institutional ownership. It also presents various performance metrics across different timeframes and analyst recommendations, offering a comprehensive snapshot of the company's current financial health and market position.
Insulin pump makers Tandem and Insulet post contrasting Q2 results
Tandem Diabetes Care and Insulet, two major insulin pump manufacturers, have reported contrasting financial results for the second quarter. While Tandem saw a decline in its pump shipments and revised its full-year guidance downwards, Insulet exceeded revenue expectations and raised its outlook for the year due to strong demand for its Omnipod 5 system. This highlights a divergence in performance within the insulin delivery device market.
Insulin pump makers Tandem and Insulet post contrasting Q2 results
This article examines the contrasting Q2 results of insulin pump manufacturers Tandem and Insulet. It delves into the specific financial performance and key factors that led to different outcomes for each company during the quarter.
Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026
Tandem Diabetes Care (NASDAQ: TNDM) will report its second-quarter 2026 financial results on August 6, 2026, after the market closes. The company will also host a conference call and live webcast to discuss the results, providing an opportunity for investors and interested parties to hear management's commentary and updates.
What Tandem Diabetes Care (TNDM)'s CGM Expansion and New Tubeless Rival Mean For Shareholders
Tandem Diabetes Care recently expanded its t:slim X2 insulin pump's compatibility with Abbott's FreeStyle Libre 3 Plus CGM in Europe, while facing new competition from Modular Medical's Pivot tubeless insulin patch pump. This dual development highlights both the growth of Tandem's ecosystem and increasing competitive pressures in the insulin delivery market. The article suggests this situation could lead to a mix of international expansion opportunities and risks from new tubeless rivals for Tandem shareholders.
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
Tandem Diabetes Care announced the launch of t:slim X2 insulin pump compatibility with Abbott’s FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in the United Kingdom, Switzerland, Sweden, Finland, and Italy. This integration expands CGM choices for users of the t:slim X2 pump with Control-IQ+ automated insulin delivery technology. Additional countries, including Belgium, the Netherlands, and Germany, are expected to gain this compatibility in 2026.
Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets
Tandem Diabetes Care has launched the compatibility of its t:slim X2 insulin pump with Abbott's FreeStyle Libre 3 Plus continuous glucose monitoring (CGM) sensor in five international markets: the UK, Switzerland, Sweden, Finland, and Italy. This integration provides more CGM choice for users of Tandem's Control-IQ+ automated insulin delivery technology, with plans to expand to additional countries like Belgium, the Netherlands, and Germany in 2026. The FreeStyle Libre 3 Plus sensor offers 15-day wear and sends minute-by-minute glucose readings to the pump and mobile app.
TNDM - Tandem Diabetes Care Inc Latest SEC Filings
This article provides comprehensive financial data and performance metrics for Tandem Diabetes Care Inc. (TNDM). It highlights key figures such as the last closing price, market capitalization, income, sales, various financial ratios, and stock performance over different periods. The data indicates recent stock movement, insider and institutional ownership, and profitability margins.
Why Tandem Diabetes (TNDM) Shares Are Sliding Today
Shares of Tandem Diabetes Care (NASDAQ:TNDM) fell 2.5% after Modular Medical, a company founded by Tandem's original founder, introduced a new competing tubeless insulin patch pump. This news has raised concerns among investors about increased competition and potential market share loss for Tandem Diabetes. Despite an initial drop, the stock rebounded slightly, and analysts previously upgraded Tandem due to a positive outlook on its pharmacy channel.
Press Release: Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026
Tandem Diabetes Care (NASDAQ: TNDM) will release its second quarter 2026 financial results on August 6, 2026, after the market closes. The company will also host a conference call and live webcast to discuss these results at 4:30 p.m. ET (1:30 p.m. PT) on the same day. Investors can access the event via webcast or by dialing in.
Why Tandem Diabetes (TNDM) Shares Are Sliding Today
Shares of Tandem Diabetes Care (TNDM) fell 2.5% after Modular Medical, a company founded by Tandem's original founder, announced the first patient use of its new tubeless insulin patch pump, Pivot. This news signals increased competition in the diabetes technology market, causing investor concern about Tandem's potential loss of market share. Despite an earlier upgrade by Wells Fargo and positive Q2 sales signals, TNDM shares are down 28.4% since the beginning of the year.
Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh
This page provides access to financial disclosures and regulatory filings for Tandem Diabetes Care, Inc., specifically for its unsponsored Brazilian Depositary Receipts (T2ND34). It lists various documents from 2025 and 2026, including earnings reports, conference transcripts, and corporate presentations, offering insights into the company's performance, strategy, and upcoming products. The documents cover key events such as the Goldman Sachs and Bank of America Healthcare Conferences, quarterly earnings calls, and the company's annual general meeting.
Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) will announce its second quarter 2026 financial results after market close on Thursday, August 6, 2026. The company will host a conference call and webcast on the same day at 4:30 pm Eastern Time to discuss these results. A live webcast will be available on their Investor Center website.
Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026
Tandem Diabetes Care, Inc. (Nasdaq: TNDM) will release its second quarter 2026 financial results on Thursday, August 6, 2026, after market close. The company will host a conference call and webcast on the same day at 4:30 pm ET to discuss the results. An archive of the webcast will be available on their Investor Center website.
The Technical Signals Behind (TNDM) That Institutions Follow
This article analyzes Tandem Diabetes Care Inc. (NASDAQ: TNDM), highlighting positive near-term sentiment within a long-term strength context, despite a weak mid-term bias. It identifies a strong risk-reward setup, with an exceptional 96.8:1 ratio, targeting a 30.8% gain against 0.3% risk. The piece also details three AI-generated trading strategies—position, momentum breakout, and risk hedging—tailored to different risk profiles.
Why Did TNDM Stock Jump 5% After Hours Despite Q4 Earnings Miss?
Tandem Diabetes Care (TNDM) stock rose 5% after hours despite an earnings miss, driven by record Q4 revenue, strong margins, and a strategic shift to a recurring, pharmacy-based revenue model. The company reported $290.4 million in Q4 revenue, surpassing estimates, and achieved over $1 billion in annual worldwide sales for the first time. Tandem also provided a 2026 revenue outlook and highlighted upcoming product milestones and improved projected margins.
Tandem Diabetes Care, Inc. Actuals & Estimates (BIVA:TNDM)
This article provides an overview of Tandem Diabetes Care, Inc. (TNDM) stock, including its financial actuals and estimates, market capitalization, and analyst forecasts. It details the company's recent earnings, revenue, net income, and EBITDA, and states that TNDM does not pay dividends. The article also provides information on how to buy TNDM stocks and future earnings report dates.
Price to earnings forward of Tandem Diabetes Care, Inc. – NASDAQ:TNDM
The article focuses on the "Price to earnings forward" metric for Tandem Diabetes Care, Inc. (NASDAQ: TNDM) as presented on TradingView. It appears to be a financial data snippet rather than a news article, indicating the value and changes for this specific financial indicator.
Price to sales forward of Tandem Diabetes Care, Inc. – NASDAQ:TNDM
This article displays the "Price to sales forward" data for Tandem Diabetes Care, Inc. (NASDAQ: TNDM) on the TradingView platform. It presents the company's financial overview, specifically highlighting a key valuation metric for investors and analysts. The content focuses solely on this financial data point within the context of the TradingView interface.
Tandem Diabetes Care, Inc. Actuals & Estimates (BMV:TNDM)
This article provides an overview of Tandem Diabetes Care, Inc. (BMV:TNDM) stock, including its current price, market capitalization, and analyst forecasts. It also covers financial details such as past earnings, revenue, and upcoming earnings dates, noting that the company does not pay dividends.
Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.066666 Sh
This page provides financial actuals and estimates for Tandem Diabetes Care, Inc. Shs Unsponsored Brazilian Depositary Receipt (T2ND34) traded on B3. Users can explore reported financial data and analyst estimates, comparing actual results with average, high, and low estimates across income statements, balance sheets, and cash flow statements. The platform allows for visualization of trends over time for both annual and quarterly data.
Tandem Diabetes rises on Wells Fargo upgrade
Tandem Diabetes Care (TNDM) stock rose following an upgrade from Wells Fargo. Analyst Larry Biegelsen increased the rating to Equal Weight from Underweight and raised the price target to $32 from $25, citing an improved outlook for the company's insulin pump business. The upgrade is attributed to positive changes in the competitive landscape, particularly with Insulet (PODD) and DexCom (DXCM).
Tandem Diabetes rises on Wells Fargo upgrade
Tandem Diabetes (TNDM) stock rose following an upgrade from Wells Fargo. The upgrade signals a positive outlook from the financial institution regarding the company's future performance. This news is expected to influence investor sentiment and potentially impact TNDM's market valuation.
TNDM Initiated Coverage by Deutsche Bank -- Rating Set to Hold
Deutsche Bank has initiated coverage on Tandem Diabetes Care (TNDM) with a "Hold" rating and a price target of $15.50. Despite GuruFocus indicating the stock is significantly undervalued at $14.18 with a GF Value™ of $29.84, TNDM's GF Score™ of 59/100, combined with mixed analyst sentiments and low financial strength, suggests caution for investors. No insider trading activity has been reported in the past three months.
Deutsche Bank initiates Tandem Diabetes stock with hold rating
Deutsche Bank initiated coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Hold rating and a price target of $15.50, citing execution risk and complexity amid multiple transitions. The company has stabilized its business, launched its smaller Mobi pump, and is transitioning to a paygo pharmacy model, which is expected to double revenue per patient compared to its legacy business. Despite recent record revenue and sales figures in Q1 2026 and expanded CE mark approval for its insulin delivery systems, analysts do not anticipate profitability this year.
Deutsche Bank Initiates Coverage on Tandem Diabetes Care With Hold Rating, $15.50 Price Target
Deutsche Bank has initiated coverage on Tandem Diabetes Care (TNDM) with a Hold rating and set a price target of $15.50. This comes after recent news including Wells Fargo upgrading the stock to Overweight and various corporate presentations and earnings reports. Tandem Diabetes Care, a company specializing in advanced automated insulin delivery systems, has seen fluctuating analyst ratings and price targets.
Tandem Diabetes Care Inc (TNDM) Valuation: PE, PB & Fair Value Analysis
Tandem Diabetes Care Inc (TNDM) has a current valuation score of 7.61, ranking 149 out of 203 in the Healthcare Equipment & Supplies industry. The article notes that the company's current P/E ratio is -10.43, which is significantly below its recent high and above its recent low. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Tandem Diabetes Care Inc (TNDM) Earnings Forecast: Future EPS & Revenue Growth Estimates
Tandem Diabetes Care Inc (TNDM) has an earnings forecast score of 7.33, ranking 142nd in its industry. Analysts have a consensus "Buy" rating with an average price target of $18.00 and an expected upside of 74.22%. The company's next quarter revenue is projected at $255.18 million, and EPS is expected to be -$0.33.
Tandem Diabetes Care Inc (TNDM) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Tandem Diabetes Care Inc (TNDM), highlighting its volatility and financial risks. The company's risk assessment score is 5.08, placing it 86th out of 204 in its industry, with a beta of 1.59 indicating higher volatility compared to the S&P 500 index. The assessment covers maximum drawdown, return-to-drawdown ratios, and various volatility metrics over different timeframes.
Tandem Diabetes Care Inc (TNDM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Tandem Diabetes Care Inc (TNDM) by business segment and region. As of April 6, the company's revenue is primarily driven by its Pump segment, contributing 69.67%, with significant
Precision Trading with Tandem Diabetes Care Inc. (TNDM) Risk Zones
This article provides a precision trading analysis for Tandem Diabetes Care Inc. (TNDM), highlighting neutral near and mid-term readings but a positive long-term bias. It outlines various trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis and current risk parameters.
Precision Trading with Tandem Diabetes Care Inc. (TNDM) Risk Zones
This article by Stock Traders Daily provides a detailed analysis of Tandem Diabetes Care Inc. (TNDM) stock, highlighting neutral near and mid-term readings but a positive long-term bias. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry, target, and stop-loss levels. The analysis also identifies elevated downside risk due to a lack of additional long-term support signals.
Tandem Diabetes Care Inc (TNDM) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Tandem Diabetes Care Inc (TNDM) focusing on its dividend and stock split history. It indicates that TNDM has not distributed any dividends over the past five years and has no recorded stock split data. The piece presents current stock information including its market cap and recent price movements.
Tandem Diabetes (NASDAQ: TNDM) Rule 144 notice to sell 361 shares
Tandem Diabetes Care (NASDAQ: TNDM) has filed a Rule 144 notice to sell 361 shares of common stock derived from Restricted Stock Units, with the proposed sale method dated June 15, 2026. This filing also reveals a previous 10b5-1 sale of 266 shares by Mark Novara on May 19, 2026. The identified broker for the proposed sale is Morgan Stanley Smith Barney LLC.
TNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin Up
Tandem Diabetes Care (TNDM) reported a narrower Q1 2026 loss of 30 cents per share, beating the Zacks Consensus Estimate, with revenues up 5.5% year over year to $247.2 million, also exceeding expectations. Despite these positive results and an expanded gross margin to 55.3%, the company's stock dropped 23.6% following the earnings announcement. Tandem Diabetes maintains its full-year sales guidance of $1.065 billion to $1.085 billion and projects a gross margin of 56% to 57%.
Tandem Diabetes Care (TNDM) Stock Valuation Check After Recent Share Price Volatility
Tandem Diabetes Care (TNDM) has experienced significant stock price volatility, with a 29% gain in the last month but a 24% decline over the past three months and year-to-date. The company's stock is currently trading at $16.60, well below the analyst price target of $29.20, leading to a "43.2% Undervalued" narrative. This valuation is largely based on expectations of increased recurring pump supply sales, pharmacy expansion, and international distribution growth, despite competitive pressures and potential setbacks in these areas.
Tandem Diabetes Care Inc (TNDM) Shares Surge 5.1% -- What GF Score of 65 Tells Investors
Tandem Diabetes Care Inc (TNDM) saw its shares surge 5.1% to $16.60, despite a "Possible Value Trap" label due to low financial strength and profitability. GuruFocus's GF Value™ indicates the stock is 44.3% undervalued compared to its $29.80 estimate, while its GF Score™ of 65/100 suggests above-average overall potential, driven by strong growth. Insiders have shown no buying activity, selling $0.0M in the past three months, prompting caution for potential investors.
Tandem Diabetes Care Receives CE Mark Expansion for Type 2 Diabetes and Pregnancy Use of AID Systems
Tandem Diabetes Care has received expanded CE mark approvals in Europe for its t:slim X2 and Tandem Mobi automated insulin delivery (AID) systems. The expanded indications allow these systems to be used by adults with type 2 diabetes and by individuals managing type 1 diabetes during pregnancy, significantly broadening access to advanced glucose management technology. This milestone is supported by clinical trials demonstrating improved time in target glucose range for pregnant individuals and significant A1C reduction for type 2 diabetes patients.
Why Insulet thinks its fully closed loop system will stand apart from rivals
Insulet is developing a "fully closed loop" automated insulin delivery system for Type 2 diabetes that distinguishes itself from competitors by requiring no carb-counting, insulin bolusing, or initial programming by physicians. The system, which automated dose titration and has no bolus button, showed promising results in its Evolution 3 study, improving participants' time in range and reducing total daily insulin without weight gain. Insulet also shared findings for its Omnipod 6 algorithm, designed for both Type 1 and Type 2 diabetes, which offers a lower glucose target and improved connectivity, with an FDA submission planned for this year and a launch next year.
BofA Securities Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $25
BofA Securities has reiterated its Hold rating on Tandem Diabetes Care (TNDM.US) and maintained its target price at $25. This indicates a neutral outlook on the company's stock from BofA Securities.
Should Tandem’s Expanded EU Diabetes Indications and ESOP Shelf Filing Require Action From Tandem Diabetes Care (TNDM) Investors?
Tandem Diabetes Care recently filed a US$47.40 million shelf registration for employee stock ownership and secured CE mark approval in Europe to expand the use of its automated insulin delivery systems for pregnancy in type 1 diabetes and adults with type 2 diabetes. This broader European certification could reinforce Tandem's role in integrated diabetes management and support its international growth, though competitive pressures remain a key risk. The article examines how these developments might influence Tandem's investment narrative, which forecasts $1.4 billion revenue and $63.4 million earnings by 2029.
TNDM: Momentum builds with pharmacy transition, Mobi Tubeless launch, and international expansion
Tandem Diabetes Care (TNDM) is seeing strong momentum driven by product innovation, including the CE Mark for pregnancy indication and the upcoming Mobi Tubeless launch. The company is also progressing with its pharmacy channel transition to reduce costs and boost growth, alongside plans for international expansion and new technology initiatives to strengthen its market position. This positive outlook was highlighted at the Goldman Sachs 47th Annual Global Healthcare Conference.
Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy
Tandem Diabetes Care has received CE Mark approval for its t:slim X2 and Tandem Mobi automated insulin delivery systems for expanded indications in Europe. These systems, utilizing Control-IQ+ AID technology, are now approved for use by individuals with type 1 diabetes during pregnancy and adults with type 2 diabetes. This expansion aims to broaden access to their AID technology and improve lives across the diabetes community, backed by clinical trial data published in JAMA and the New England Journal of Medicine.
Tandem insulin pumps cleared in EU for expanded indications
This article announces that Tandem Diabetes Care has received expanded indications in the EU for its t:slim X2 insulin pump with Control-IQ technology and t:slim X2 pump with Basal-IQ technology, including younger users and integrated continuous glucose monitoring. The expanded clearances allow for treatment of Type 1 diabetes in patients as young as two years old across the EU. These developments build on previous CE mark approvals for both systems.
Tandem Diabetes’ Insulin Pumps Win EU Nods for T2D, T1D in Pregnancy
Tandem Diabetes Care has received CE mark approval in Europe for its t:slim X2 and Tandem Mobi insulin pumps using Control-IQ+ AID technology. This expanded indication allows their use for people with type 1 diabetes during pregnancy and adults with type 2 diabetes. The approval for type 1 diabetes in pregnancy is based on the CIRCUIT trial, showing improved time in glucose target range, while the type 2 diabetes approval stems from the 2IQP trial, which demonstrated significant A1C reduction.
